13.68
전일 마감가:
$14.11
열려 있는:
$14.03
하루 거래량:
4.46M
Relative Volume:
1.90
시가총액:
$4.30B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-20.10
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+2.17%
1개월 성능:
+6.21%
6개월 성능:
+69.52%
1년 성능:
+59.44%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals Inc
|
13.68 | 4.44B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
124.82 | 53.64B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.23 | 54.24B | 29.62B | 260.04M | 5.51B | 0.0787 |
|
HLN
Haleon Plc Adr
|
10.47 | 45.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.08 | 37.94B | 17.39B | 1.43B | 774.28M | 1.219 |
|
UTHR
United Therapeutics Corp
|
469.49 | 20.14B | 3.13B | 1.27B | 1.12B | 26.39 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Opioid Settlement And Index Inclusion Reframe Amneal Pharmaceuticals Risk And Reach - Yahoo Finance
Published on: 2026-01-30 06:37:48 - baoquankhu1.vn
Amneal initiates nationwide opioid settlement (AMRX:NASDAQ) - Seeking Alpha
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan - TipRanks
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index - The Manila Times
Amneal Pharma To Settle Majority Of Opioids-Related Claims - TradingView
Amneal Pharmaceuticals Finalizes Nationwide Opioids Settlement - TradingView
Amneal Pharmaceuticals, Inc. Added to S&P SmallCap 600® Index - Quiver Quantitative
Drugmaker Amneal joins S&P small-cap index investors track - Stock Titan
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
Amneal, LegalZoom, others rise as S&P Dow Jones Indices announces index changes - Investing.com Canada
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year HighStill a Buy? - MarketBeat
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 - The Manila Times
Amneal Pharmaceuticals to detail 2025 results in Feb. 27 webcast - Stock Titan
Can Amneal Pharmaceuticals Inc. be the next market leaderWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
Risk Recap: Can Amneal Pharmaceuticals Inc. be the next market leaderNew Guidance & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Amneal Pharmaceuticals Inc. continue delivering strong returnsJuly 2025 Volume & AI Enhanced Trading Alerts - mfd.ru
Stock Recap: Is ACAD in a bullish channelJuly 2025 Short Interest & Smart Allocation Stock Reports - baoquankhu1.vn
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum - Sahm
Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN
Profit Recap: Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's Why - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.48 - Investing.com
Gains Recap: Is Amneal Pharmaceuticals Inc stock undervalued right nowCEO Change & Community Consensus Picks - baoquankhu1.vn
Geopolitics Watch: Should I buy KNTK stock nowWeekly Stock Analysis & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Increase in Short Interest - MarketBeat
Portfolio Recap: Can Amneal Pharmaceuticals Inc be the next market leader2025 Analyst Calls & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Amneal unveils new brand identity to reimagine access to medicine - MediaNews4U
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - sharewise.com
Trade Recap: Is Amneal Pharmaceuticals Inc a potential multi baggerPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug PostEarnings: Will Fastenal Company benefit from rate cutsRecession Risk & Trade Opportunity Analysis Reports - baoquankhu1.vn
Mycophenolate Pregnancy Registry: Key Insights for Investors - MSN
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run - Yahoo Finance
Amneal unveils bold new brand to reimagine what’s possible in making medicine accessible for all - Pharmabiz.com
Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report - TipRanks
Amneal Pharma Expects To Meet Or Exceed Its 2025 Full-Year Financial Guidance - TradingView — Track All Markets
Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Keiferx collaborates with Amneal on KFRX-06 for Parkinson’s - BioWorld MedTech
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 - Insider Monkey
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Nasdaq Moves: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Levels & Weekly Stock Breakout Alerts - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsWeekly Investment Recap & Precise Swing Trade Entry Alerts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock recover faster than peersStability vs Neutral Overview & HOKA model picks for your routine - ulpravda.ru
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):